NVIDIA Corporation (NVDA.US) drives the application of AI in the medical field, in collaboration with Illumina (ILMN.US) and Mayo Clinic.

NVIDIA Corporation (NVDA.US) announced a partnership with genetic sequencing company Illumina Inc. (ILMN.US), Mayo Clinic, and several other medical institutions to accelerate the application of artificial intelligence (AI) technology in the healthcare industry. This is part of the efforts by the world's largest chip manufacturer to promote the widespread use of AI. According to a statement released on Monday, Illumina will utilize NVIDIA Corporation's generative AI platform for applications in the fields of chemistry and biology; Mayo Clinic plans to deploy NVIDIA Corporation's latest hardware and some software to enhance efficiency in digital pathology. NVIDIA Corporation is a leading company in AI workload chip technology, and this collaboration was announced before the annual healthcare conference hosted by J.P. Morgan in San Francisco. NVIDIA Corporation CEO Jensen Huang is scheduled to speak at the conference, where he will discuss the importance of the medical and pharmaceutical industries as key areas for the expansion of the company's AI products. Despite the global healthcare market being worth up to $10 trillion, which represents a huge opportunity for NVIDIA Corporation, the company has not disclosed specific revenue data from such collaborations. NVIDIA Corporation's chips are core components in building new servers for AI software. Huang predicts that the widespread use of AI technologies like virtual assistants and Siasun Robot & Automation will drive a new industrial revolution. Apart from traditional data center clients, NVIDIA Corporation is actively working to expand its AI technology to more sectors of the economy. Executives at NVIDIA Corporation are optimistic about the potential of using their powerful AI products in the healthcare industry. For example, in drug development, AI can speed up the tedious logistical tasks in clinical trials, such as scheduling and record-keeping. AI agents will become important tools to help improve efficiency. Additionally, NVIDIA Corporation also provides a "blueprint" combining hardware and software to accelerate protein design. More research will be done through computer simulations and virtual screening, thus reducing the need for actual physical laboratory experiments. NVIDIA Corporation states that these technologies will significantly shorten the drug development cycle. The company's executives also suggest that AI technology could generate virtual DIGIHUMAN models based on pathological data. Furthermore, the company predicts that AI will shift drug design from the traditional laboratory discovery mode to a fully computer-driven mode. This transformation will greatly enhance research and development efficiency. The company also envisions the application of AI in the physical world. It believes that NVIDIA Corporation's technology will be used in thousands of operating rooms and billions of hospital devices. Large computers based on NVIDIA Corporation chips will train and test medical devices through simulation techniques in the virtual world, accelerating the implementation of intelligent machines in the healthcare industry. NVIDIA Corporation is driving the application of AI technology in the healthcare industry through a series of initiatives and expects this sector to become a new growth engine for its business. This strategy not only highlights the potential of AI technology to transform the healthcare industry but also reflects NVIDIA Corporation's forward-thinking layout in the AI era.